Sugi Predict

Sugi Predict / Compounds / SCHEMBL18322246

SCHEMBL18322246

SCHEMBL18322246

CCOC(=O)c1[nH]c2cccnc2c1-c1ccc(C)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE9A O76083 1/20 0.51
▸ ALDH1A1 P00352 8/20 0.49
▸ HPGD P15428 4/20 0.49
▸ CYP1A2 P05177 1/20 0.49
▸ XBP1 P17861 1/20 0.49
▸ CYP2C19 P33261 1/20 0.49
▸ KDM4E B2RXH2 5/20 0.46
▸ MAPT P10636 3/20 0.46
▸ RAB9A P51151 3/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.46
▸ NPC1 O15118 1/20 0.46
▸ TP53 P04637 1/20 0.46
▸ GAA P10253 1/20 0.46
▸ NPSR1 Q6W5P4 2/20 0.43
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ MMP2 P08253 2/20 0.42
▸ MMP13 P45452 2/20 0.42
▸ MMP14 P50281 2/20 0.42
▸ HTR6 P50406 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13761304 0.91 ALDH1A1 (0.47) PDE9AALDH1A1HPGDCYP1A2XBP1
SCHEMBL18322245 0.91 ALDH1A1 (0.58) ALDH1A1HPGDCYP1A2XBP1CYP2C19
SCHEMBL3878261 0.87 AR (0.55) ALDH1A1HPGDCYP1A2XBP1CYP2C19
SCHEMBL29030308 0.83 PDE9A (0.56) PDE9AALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL13926319 0.80 MAPT (0.47) ALDH1A1HPGDCYP1A2XBP1CYP2C19
SCHEMBL3881195 0.80 KDM4E (0.45) ALDH1A1HPGDCYP1A2KDM4EMAPT
SCHEMBL13447133 0.80 KDM4E (0.56) ALDH1A1HPGDCYP1A2KDM4EMAPT
SCHEMBL4882360 0.80 ALDH1A1 (0.47) ALDH1A1HPGDCYP1A2XBP1CYP2C19
SCHEMBL13447132 0.76 NPC1 (0.45) ALDH1A1HPGDCYP1A2KDM4EMAPT
SCHEMBL3883122 0.74 HPSE (0.50) PDE9ACYP1A2CYP2C19KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12049465-B2 Tricyclic compounds and their use as phosphodiesterase inhibitors PFIZER INC. (US) 2024-07-30 — — US disclosed
CN-107787322-B Tricyclic compounds and their use as phosphodiesterase inhibitors 辉瑞大药厂 2023-07-07 — — CN disclosed
US-20230146535-A1 TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS PFIZER INC. (US) 2023-05-11 — — US disclosed
US-20230146535-A1 TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS PFIZER INC. (US) 2023-05-11 — — US disclosed
US-20230146535-A1 TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS PFIZER INC. (US) 2023-05-11 — — US disclosed
US-20230002386-A1 TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS PFIZER INC. (US) 2023-01-05 — — US disclosed
US-20230002386-A1 TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS PFIZER INC. (US) 2023-01-05 — — US disclosed
US-11472805-B2 Tricyclic compounds and their use as phosphodiesterase inhibitors PFIZER, INC. (US) 2022-10-18 — — US disclosed
EP-3766885-B1 TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS PFIZER (US) 2022-05-25 — — EP disclosed
EP-3766885-B1 TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS PFIZER (US) 2022-05-25 — — EP disclosed
EP-3766885-A1 TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS Pfizer Inc (US) 2021-01-20 — — EP disclosed
EP-3766885-A1 TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS Pfizer Inc (US) 2021-01-20 — — EP disclosed
EP-3310784-B1 TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS. PFIZER (US) 2020-10-07 — — EP disclosed
EP-3310784-B1 TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS. PFIZER (US) 2020-10-07 — — EP disclosed
US-20190263816-A1 Tricyclic Compounds And Their Use As Phosphodiesterase Inhibitors PFIZER INC. (US) 2019-08-29 — — US disclosed
US-20190263816-A1 Tricyclic Compounds And Their Use As Phosphodiesterase Inhibitors PFIZER INC. (US) 2019-08-29 — — US disclosed
EP-3310784-A1 TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS Pfizer Inc (US) 2018-04-25 — — EP disclosed
WO-2016203347-A1 TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS PFIZER INC. (US) 2016-12-22 — — WO disclosed
WO-2016203347-A1 TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS PFIZER INC. (US) 2016-12-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12049465-B2 Tricyclic compounds and their use as phosphodiesterase inhibitors PDE3B, PDE3A, PDE5A PDE9A 14/4885ALDH1A1 972/4885HPGD 508/4885
US-20230146535-A1 TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS PDE3B, PDE3A, PDE5A PDE9A 14/4885ALDH1A1 972/4885HPGD 508/4885
US-11472805-B2 Tricyclic compounds and their use as phosphodiesterase inhibitors PDE3B, PDE3A, PDE5A PDE9A 14/4885ALDH1A1 972/4885HPGD 508/4885
US-20190263816-A1 Tricyclic Compounds And Their Use As Phosphodiesterase Inhibitors PDE3B, PDE3A, PDE5A PDE9A 14/4885ALDH1A1 972/4885HPGD 508/4885
US-20230002386-A1 TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS PDE3B, PDE3A, PDE5A PDE9A 14/4885ALDH1A1 972/4885HPGD 508/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.